A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Inclusion Criteria:
Exclusion Criteria:
Chicago, Illinois 60637-1447, United States
New York, New York 10021, United States
Chattanooga, Tennessee 37404, United States
Guangdong Province Guangzhou City, 510515, China
Tianjin, 300020, China
Wuhan, 430022, China
Wuhan, 430030, China
Erlangen, 91054, Germany
Hokkaido, 060-8648, Japan
Mexico, Tlaxcala 06726, Mexico
Gda?sk, 80-214, Poland
Wroc?aw, 50-367, Poland
Jeollanam-do, 58128, South Korea
Santiago de Compostela, LA Coruna 15706, Spain
Chai Yi, 613, Taiwan
Kaoisung, 833, Taiwan
Kaoshiung, 824, Taiwan
London, NW1 2PG, United Kingdom